Natural Versus Synthetic Vitamin B Complexes in Human
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03444155 |
|
Recruitment Status :
Completed
First Posted : February 23, 2018
Last Update Posted : April 17, 2018
|
Sponsor:
Medical University of Graz
Information provided by (Responsible Party):
Priv.-Doz. Mag. Dr. Willibald Wonisch, Medical University of Graz
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
In a cross-over study the investigators evaluate the effects of natural (Panmol-B-Complex) versus synthetic vitamin B complexes to identify the bioavailability of distinct vitamins as well as long-term effects. The primary hypothesis for this study: "Natural Vitamin B-complexes are as effective as synthetic Vitamin B-complexes or better." For this reason 30 subjects (18 to 65y; BMI >19 to <29) were recruited for this study. The study population was divided into 2 groups of each 15 subjects in a cross-over trial. Vitamin supplementation consisted of Thiamine (2,77mg), Riboflavin (3,53mg), Niacin (40,32mg), Pantothenic acid (15,12mg), Pyridoxine (3,53mg), Biotin (0,13mg), Folic acid (0,50mg) and Cobalamin (6,3µg) per day in both groups. Blood samples are taken at baseline - 1.5h after vitamin supplementation - 4h - 7h - 6 weeks - wash out phase I (2 weeks); start cross-over: baseline - 1.5h after vitamin supplementation - 4h - 7h - 6 weeks - washout phase II (6 weeks). In case of main target criteria Thiamin, Riboflavin, Pyridoxine, Folic acid and Cobalamin were measured in serum as well as total peroxides (µmol/L), peroxidase-activity (U/L), total antioxidant status (mmol/L) and polyphenols (mmol/L).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Healthy Thiamine and Niacin Deficiency States Pyridoxine Deficiency Folic Acid Deficiency Anemia, Dietary Vitamin B 12 Deficiency Peroxidase; Defect Polyphenols Oxidative Stress Homocystine; Metabolic Disorder | Dietary Supplement: Panmol-B-Complex Dietary Supplement: Synthetic Vitamin B-Complex | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Vitamin B complex (natural vs. synthetic) administered in capsules each day for 6 weeks - 2 weeks wash-out phase I (2 weeks) - cross-over 6 weeks - wash-out phase II (6 weeks) |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | Masking was organized and supervised by the randomization person in charge. Group assignment was 1:1 (control vs. verum group) with identical packages for both Vitamin supplements with 126 capsules for each subject per phase. Randomization was done with sealed envelopes. |
| Primary Purpose: | Basic Science |
| Official Title: | Pilot Study for the Evaluation of the Effectiveness of Natural Versus Synthetic Vitamin B Complexes in Humans. |
| Actual Study Start Date : | May 8, 2017 |
| Actual Primary Completion Date : | October 3, 2017 |
| Actual Study Completion Date : | November 17, 2017 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Panmol-B-Complex
B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
|
Dietary Supplement: Panmol-B-Complex
B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks. |
|
Active Comparator: Synthetic Vitamin B-complex
B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
|
Dietary Supplement: Synthetic Vitamin B-Complex
B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks. |
Primary Outcome Measures :
- Serum Thiamine in µg/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statistical significant.
- Serum Riboflavin in µg/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statistical significant.
- Serum Pyridoxine in µg/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statistical significant.
- Serum Folic acid in ng/mL [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statistical significant.
- Serum Cobalamin in pg/mL [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statistical significant.
Secondary Outcome Measures :
- Serum Total peroxides in µmol/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statitical significant.
- Serum Total antioxidant capacity in mmol/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statitical significant.
- Serum Endogenous peroxidase-activity in mU/mL [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statitical significant.
- Serum Polyphenols in mmol/L [ Time Frame: 18 weeks ]A difference of p<0.05 between groups and time-points will be assessed as statitical significant.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male and female
- 18-65 y
- Healthy
Exclusion Criteria:
- Cholesterol >240mg/dl
- Study inclusion in the past 2 months
- Pregnancy and lactation period
- Clinical diagnosis of chronic infections
- Ingestion of trace elements, vitamin- and fatty acid supplements in the past 3 months
- Clinical diagnosis of cardiovascular disease
- Clinical diagnosis of cancer
- Clinical diagnosis of psychotic diseases
- Insulin dependent diabetes
- Clinical diagnosis of autoimmune diseases
- Maldigestion/Malabsorption
- Veganes cuisine
- > 1 Beer/day
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03444155
Locations
| Austria | |
| Wonisch Willibald | |
| Graz, Styria, Austria, 8036 | |
Sponsors and Collaborators
Medical University of Graz
| Responsible Party: | Priv.-Doz. Mag. Dr. Willibald Wonisch, Principal Investigator, Medical University of Graz |
| ClinicalTrials.gov Identifier: | NCT03444155 |
| Other Study ID Numbers: |
Medical University of Graz |
| First Posted: | February 23, 2018 Key Record Dates |
| Last Update Posted: | April 17, 2018 |
| Last Verified: | April 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Metabolic Diseases Vitamin B 12 Deficiency Folic Acid Deficiency Vitamin B 6 Deficiency Vitamin B Deficiency Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders |
Folic Acid Vitamin B Complex Vitamins Micronutrients Nutrients Growth Substances Physiological Effects of Drugs Hematinics |